Keep Up With McLean!
Receive the latest news in your inbox each month.
Researchers at Harvard-affiliated McLean Hospital have shown a new category of “green” nanoparticles comprised of a non-toxic, protein-based nanotechnology that can non-invasively cross the blood brain barrier and is capable of transporting various types of drugs.
In an article published May 1, 2012 online in PLOS ONE, Gordana Vitaliano, MD, director of the Brain Imaging NaNoTechnology Group at the McLean Hospital Imaging Center, reported that clathrin protein, a ubiquitous protein found in human, animal, plant, bacteria and fungi cells, can been modified for use as a nanoparticle for in-vivo studies. “Clathrin has never been modified for use in vivo and offers many new and interesting possibilities for delivering drugs and medical imaging agents into the brain,” said Vitaliano. (doi: 10.1371/journal.pone.0035821)
Clathrin is the body’s primary delivery vehicle responsible for delivering many different types of molecules into cells. Vitaliano therefore believed that the protein’s naturally potent transport capabilities might be put to practical medical use for drug delivery and medical imaging.
“This study provides a new insight into utilizing bioengineered clathrin protein as a novel nanoplatform that passes the blood brain barrier,” said Vitaliano, who successfully attached different fluorescent labels, commonly used in imaging, to functionalize clathrin nanoparticles. “We were able to show that the clathrin nanoparticles could be non-invasively delivered to the central nervous system (CNS) in animals. The clathrin performed significantly.”
Of major importance for future clinical applications, Vitaliano also showed that clathrin crossed and/or bypassed the blood-brain barrier without enhancers or modifications, unlike other nanoparticles. These findings open the door to exploring new and important CNS medical applications.
One important medical application for clathrin nanoparticles would be Magnetic Resonance Imaging (MRI). Gadolinium contrast agents are often used to improve MRI performance. In one configuration, Vitaliano found that functionalized clathrin nanoparticles performed 8,000 times better than an FDA approved MRI contrast agent (gadopentetate dimeglumine).
“Stated another way, it means 8,000 times less gadolinium might be required for achieving good MRI results. Because very low gadolinium concentrations would be required for MRI, it could significantly decrease gadolinium toxicity, which is an important issue,” explained Vitaliano. “Clathrin transported gadolinium is therefore among the most potent, biocompatible contrast agents available.”
These results in two different applications showed that clathrin offers substantial functionalization and transport flexibility. Purified clathrin nanoparticles could therefore serve as an appealing alternative to other medical nanoplatforms such as dendrimers, nanogels, solid lipid nanospheres, liposomes, and the like.
Given the critical need for new types of CNS drug transport capabilities, Vitaliano said her work would likely be of interest to researchers involved in neuroimaging and neuroscience, but also to radiologists, bioengineers, chemists, physicists, material scientists, biomedical researchers, and other researchers active at the frontiers of imaging and drug delivery.
Looking ahead, Vitaliano noted that her findings may also facilitate other studies for examining signaling pathways in different diseases that rely in whole or in part on clathrin transport, and thus may have a substantial impact in multiple fields.